A clinical study to determine the efficacy and safety of an investigational medication in the treatment of depression.

Condition	Treatment or Intervention	Phase
Major Depressive Disorder		Phase II Phase III

Ages Eligible for Study:  65 Years and above,  Genders Eligible for Study:  Both

Criteria

Patients with Major Depressive Disorder

Alabama
      Call for Information, Birmingham,  Alabama,  35216,  United States
Arizona
      Call for Information, Phoenix,  Arizona,  85020,  United States
      Call for Information, Peoria,  Arizona,  35381,  United States
Arkansas
      Call for Information, Little Rock,  Arkansas,  72205,  United States
California
      Call for Information, Rancho Mirage,  California,  92270,  United States
      Call for Information, San Francisco,  California,  94118,  United States
      Call for Information, Fresno,  California,  93720,  United States
      Call for Information, Anaheim,  California,  92805,  United States
      Call for Information, San Diego,  California,  92123,  United States
Florida
      Call for Information, Boca Raton,  Florida,  33433,  United States
      Call for Information, Sarasota,  Florida,  34232,  United States
      Call for Information, St. Petersburg,  Florida,  33702,  United States
      Call for Information, Jacksonville,  Florida,  32257,  United States
      Call for Information, Ft. Myers,  Florida,  33901,  United States
Kansas
      Call for Information, Wichita,  Kansas,  67214,  United States
Maryland
      Call for Information, Baltimore,  Maryland,  21208,  United States
Massachusetts
      Call for Information, Boston,  Massachusetts,  02115,  United States
Mississippi
      Call for Information, Ridgeland,  Mississippi,  39157,  United States
Missouri
      Call for Information, St. Charles,  Missouri,  63301,  United States
Nebraska
      Call for Information, Omaha,  Nebraska,  68105,  United States
Nevada
      Call for Information, Las Vegas,  Nevada,  89146,  United States
New Jersey
      Call for Information, Piscataway,  New Jersey,  08855,  United States
New York
      Call for Information, White Plains,  New York,  10605,  United States
      Call for Information, Rochester,  New York,  14642,  United States
      Call for Information, Staten Island,  New York,  10305,  United States
      Call for Information, New York,  New York,  10016,  United States
Ohio
      Call for Information, Beachwood,  Ohio,  44122,  United States
Oklahoma
      Call for Information, Oklahoma City,  Oklahoma,  73118,  United States
Pennsylvania
      Call for Information, Philadelphia,  Pennsylvania,  19124,  United States
Texas
      Call for Information, Austin,  Texas,  78756,  United States
      Call for Information, San Antonio,  Texas,  78229,  United States
Vermont
      Call for Information, Burlington,  Vermont,  05401,  United States
West Virginia
      Call for Information, Charleston,  West Virginia,  25301,  United States
Wisconsin
      Call for Information, Milwaukee,  Wisconsin,  53226,  United States

Study ID Numbers:  3N25
Record last reviewed:  July 2004
Last Updated:  October 13, 2004
Record first received:  May 2, 2002
ClinicalTrials.gov Identifier:  NCT00035048
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08